Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Towards clinical trials for a novel treatment for stroke

Obiettivo

Stroke is the leading cause of adult disability and represents a major health problem in the EU and the Western world. Despite available acute care treatment and rehabilitation therapies, more than half of the patients remain disabled and there is a large unmet medical need accordingly. Regeneration of interrupted nerve fiber tracts and plastic “hardware” changes in the adult mammalian central nervous system are extremely restricted, a phenomenon which represents a key reason for the low degree of recovery following CNS injuries including stroke. The molecular impediments that form the basis of this phenomenon are neurite growth inhibitory proteins expressed in central nervous system myelin, in particular the membrane protein Nogo-A which was discovered by our group. Importantly, antibodies directed against Nogo-A have been shown to induce axonal regeneration, enhance plastic circuit rearrangements and mediate significant improvements in functional recovery in rodent and non-human primate models of stroke and spinal cord injury. As recently shown in the ERC advanced grant supported the project ‘Nogorise’, almost full functional recovery was observed in rats with large strokes when anti-Nogo-A antibody treatment was followed by intensive rehabilitative training. As currently no therapy for human stroke patients beyond acute care and rehabilitation exists, there is a substantial market opportunity for the anti- Nogo-A therapy. The proposed activities within the present project aim at further establishing preclinical proof-of-concept for an anti-Nogo-A administration paradigm translatable to human stroke patients and development of human antibodies targeting Nogo-A. The expected data package will allow the critical transition from preclinical to clinical development and support the development of a comprehensive business strategy.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2016-PoC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITAT ZURICH
Contributo netto dell'UE
€ 150 000,00
Indirizzo
RAMISTRASSE 71
8006 Zurich
Svizzera
Regione
Schweiz/Suisse/Svizzera Zürich Zürich
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 150 000,00

Beneficiari (1)